LifeStance Health Group Inc

LFST remains in a Stage 2 advancing uptrend, and following a steep overbought rally it has pulled back into the rising 9/21 EMA support zone. Short-term timing is favorable, warranting a buy now on this pullback. A decisive break below the EMAs would invalidate the medium-term bullish bias.

• ↑Q1 2026 revenue climbed 21% YoY to $403M
• ↑Visit volumes increased 18% YoY to 2.5M sessions
• ↓Profitability score indicates cost‐management issues; earnings yield is negative